Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
US FDA REJECTS ABBOT'S PROSTATE CANCER DRUG

 

Abbott’s prostate cancer drug Xinlay unapprovable: US FDA

 

BY OUR PHARMA CORRESPONDENT

15 September,2005: The federal drugs regulator in US has deemed Abbott’s investigational drug against prostate cancer atrasentan unapprovable.

The US Food and Drug Administration (FDA) decision not to approve the oral investigational agent Xinlay (atrasentan) has been made on the recommendation of its Oncology Drug Advisory Committee (ODAC). The drug has been studied for the treatment of patients with hormone-refractory prostate cancer (HRPC) that has spread to the bone, Abbott announced. 

Xinlay is an investigational, oral, once-daily, non-hormonal, non-chemotherapy, agent that belongs to a class of compounds known as selective endothelin-A receptor antagonists (SERA). SERAs antagonize the effect of endothelin-l (ET-l), one of the proteins thought to be involved in the stimulation of the growth and spread of cancer cells. Abbott submitted a New Drug Application (NDA) in December 2004 seeking approval. The NDA for Xinlay supplied data on time to disease progression and delay in time to onset of bone pain.

The drug is being studied in earlier stage prostate cancer patients in an ongoing phase III study in hormone-refractory prostate cancer patients without metastasis. This study is expected to be completed in 2006.

Abbott is a global health care company developing pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 60,000 people and markets its products in more than 130 countries.

BY OUR PHARMA CORRESPONDENT

 

RELATED US FDA STORIES

All USFDA news

Dr Reddy's nizatidine generic gets FDA nod 20 Sep, 2005

Abbott’s prostate cancer drug Xinlay unapprovable: US FDA 15 Sep, 2005

US FDA rejects Pfizer's new osteoporosis drug 15 Sep, 2005

Epilepsy drug rufinamide: Eisai seeks US FDA nod 15 Sep, 2005

US FDA approves Takeda’s drug combo for type 2 diabetes

US FDA stalls Roche’ Accutane use in pregnancy

Novo Nordisk’s 24-hour acting insulin Levemir gets US FDA okay

US FDA approves Teva's generic for osteoporosis 

Barr, Teva get fexofenadine approvals from US FDA

Barr gets US FDA okay for clonazepam tabs

FDA tightens restrictions on acne drug

FDA okays acrylic lens for cataract patients 

USFDA’s recall overdrive creates panic among drug users

Roche gets USFDA approval for oral Xeloda

Glaxo applies for FDA approval for Flaurix

US FDA to decide on Plan B morning-after pill by Sept 1

Painkiller patch Duragesic under US FDA probe over patients deaths

Teva gets US FDA nod for mirtazapine anti-depressant 

FDA directs Palladone withdrawal

Zidovudine by Ranbaxy gets US FDA tentative nod

Guidant defibrillator recall: US FDA makes three classifications

AIDS drug stavudine by Aurobindo Pharma gets tentative US FDA

US FDA to source anti-HIV drugs from Indian firms

FDA warning on abortion drug Mifeprex (Mifepristone)

US FDA recalls Baxter’s intravenous pumps

US FDA grants tentative nod to Ranbaxy’s glimepiride

Barr, Teva get fexofenadine approvals from US FDA

Insomnia treatment: ROZEREM approved by FDA

US FDA grants fast track status for GSK’s HIV drug

Halozyme gets FDA nod for bladder cancer therapy

Ranbaxy gets US FDA nod for sumatriptan tabs

US FDA approval for Orchid's ceftriaxone vials

IVAX gets FDA okay for hydrochlorothiazide caps

Ranbaxy gets USFDA nod for glimepiride tabs

US FDA blocks sale of Pharmakon's illegal drugs

   Pharma Home

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us